A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE).
Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004). It is estimated that there were about 15,000 new cases of RCC in the region that excludes the Americas, European Union and Japan. Renal cell carcinomas arise from the proximal tubal epithelium are more common in males than in females with an overall lifetime risk of 1 in 75 and a median age of diagnosis of 65 years.
Everolimus (Certican®) has been approved since 2003 in more than 60 countries for the prevention of organ rejection in patients with renal and cardiac transplantation. Everolimus (RAD001) is a derivative of rapamycin, which acts as a signal transduction inhibitor. It targets mTOR, a key protein kinase regulating cell growth, proliferation, and survival. The mTOR pathway activity is modulated by the phosphatidylinositol-3-kinase (PI3K)/protein kinase B AKT (AKT) pathway, a pathway known to be deregulated in numerous human cancers. RAD001 (Afinitor®) has been investigated as an anticancer agent based on its potential to act:
- directly on the tumor cells by inhibiting tumor cell growth and proliferation;
- indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell hypoxia-inducible factor 1 (HIF-1) activity, VEGF production, and VEGF-induced proliferation of endothelial cells).
Primary: To evaluate the PFS rate over time.
Secondary:
- To evaluate the disease control rate (stable disease [SD] + partial response [PR] + complete response [CR]);
- To evaluate the objective response rate (ORR; where ORR = CR + PR) and duration;
- To describe the safety profile of RAD001.
研究概览
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Moscow、俄罗斯联邦、115478
- Novartis Investigative Site
-
Samara、俄罗斯联邦、443031
- Novartis Investigative Site
-
-
-
-
-
Cape Town、南非、7500
- Novartis Investigative Site
-
Cape Town、南非、7925
- Novartis Investigative Site
-
Durban、南非、4001
- Novartis Investigative Site
-
Parktown、南非、2193
- Novartis Investigative Site
-
-
-
-
Madhya Pradesh
-
Indore、Madhya Pradesh、印度、452 008
- Novartis Investigative Site
-
-
Maharashtra
-
Pune、Maharashtra、印度、411013
- Novartis Investigative Site
-
-
-
-
-
Alexandria、埃及、21131
- Novartis Investigative Site
-
Cairo、埃及
- Novartis Investigative Site
-
Mansoura、埃及
- Novartis Investigative Site
-
-
-
-
-
Riyadh、沙特阿拉伯、11211
- Novartis Investigative Site
-
-
-
-
-
Bangkok、泰国、10400
- Novartis Investigative Site
-
Chiang Mai、泰国、50200
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla、Hat Yai、泰国、90110
- Novartis Investigative Site
-
-
-
-
-
Ariana、突尼斯、2080
- Novartis Investigative Site
-
Sousse、突尼斯、4000
- Novartis Investigative Site
-
-
Tunisie
-
Tunis、Tunisie、突尼斯、1007
- Novartis Investigative Site
-
-
-
-
-
Amman、约旦、11941
- Novartis Investigative Site
-
-
-
-
-
Alger、阿尔及利亚、016000
- Novartis Investigative Site
-
Oran、阿尔及利亚
- Novartis Investigative Site
-
-
-
-
-
Ashrafieh、黎巴嫩、166830
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria: Patients may be entered in the study only if they meet all of the following criteria:
- Age ≥18 years old;
- Patients with advanced renal cell carcinoma with confirmed clear or non-clear cell histology, with or without nephrectomy, and with any MSKCC prognosis;
- Prior cytokine therapy is permitted;
- Patients with at least one measurable lesion at baseline as per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. If skin lesions are reported as target lesions, they must be documented (at baseline and at every physical exam) using color photography and a measuring device (such as a caliper) in clear focus to allow the size of the lesion(s) to be determined from the photograph;
- Life expectancy ≥3 months. Life expectancy should be judged in relation to other determining patient eligibility factors such as laboratory results, Karnofsky Performance Status, etc.;
- Patients with a Karnofsky Performance Status ≥70%;
- Adequate bone marrow function as shown by: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelets ≥100 x 109/L, hemoglobin (Hb) >9 g/dL;
- Adequate liver function: serum bilirubin ≤1.5 x upper limit of normal (ULN), alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5 x ULN;
- Adequate renal function: serum creatinine ≤1.5 x ULN;
- Females of childbearing potential must have had a negative serum or urine pregnancy test 7 days prior to the administration of the study treatment start;
- Patients who give a written informed consent obtained according to local guidelines.
Exclusion Criteria:Patients may not be entered into the study if they meet any of the following criteria:
- Patients within 2 weeks post-minor surgery (e.g., herniorrhaphy), 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal, or intra-pelvic) to avoid wound healing complications. Percutaneous biopsies require no waiting time prior to study entry;
- Patients with a recent history of hemoptysis, ≥0.5 teaspoon of red blood;
- Patients who have received prior systemic treatment for their metastatic RCC other than with cytokine therapy;
- Patients who received prior therapy with a VEGF pathway inhibitor, such as sunitinib, sorafenib, and bevacizumab;
- Patients who have previously received mTOR inhibitors (sirolimus, temsirolimus, everolimus, deferolimus);
- History or clinical evidence of central nervous system (CNS) metastases. Note: Subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:
Are asymptomatic; Have had no evidence of active CNS metastases for ≥6 months prior to enrollment and; Have no requirement for steroids or enzyme-inducing anticonvulsants (EIAC);
• Clinically significant gastrointestinal abnormalities including, but not limited to: Malabsorption syndrome; Major resection of the stomach or small bowel that could affect the absorption of study drug; Active peptic ulcer disease; Inflammatory bowel disease; Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation; History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning of study treatment;
- Patients receiving chronic systemic treatment with corticosteroids (dose of ≥10 mg/day methylprednisone equivalent) or another immune-suppressive agent. Inhaled and topical steroids are acceptable, as well as opotherapy after bilateral adrenal gland removal;
- Patients with a known history of human immunodeficiency virus seropositivity;
- Patients with autoimmune hepatitis;
- Patients with an active, bleeding diathesis. Patients may use coumadin or heparin preparations;
- Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study;
- Patients who have a history of another primary malignancy ≤3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of uterine;
- Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the study by both sexes. Oral contraceptives are not acceptable;
- Patients who are using other investigational agents or who had received investigational drugs ≤4 weeks prior to study treatment start; Patients unwilling or unable to comply with the protocol.
Other protocol-defined inclusion/exclusion may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:RAD001
|
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PFS (Progression-Free Survival)
大体时间:Approximately 4 years
|
the time from the date of the start of RAD001 treatment to the date of the first documented disease progression or death due to any cause
|
Approximately 4 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease Control Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]);
大体时间:Approximately 4 years
|
The disease control rate was based on the data as per local radiological review following the RECIST criteria.
The disease control rate is defined as the proportion of patients with CR, PR, or SD and was summarized in terms of percentage with 95% exact Clopper-Pearson CIs
|
Approximately 4 years
|
|
Objective Response Rate (ORR; Where ORR = CR + PR)
大体时间:Approximately 4 years
|
The overall tumor response was based on the data as per local radiological review, following RECIST criteria.
The ORR is defined as the proportion of patients with CR or PR and was summarized in terms of percentage with 95% exact Clopper-Pearson CIs
|
Approximately 4 years
|
|
Duration of Response (DOR)
大体时间:Approximately 4 years
|
The DOR analysis applied only to patients whose overall response was CR or PR and was defined as the time from onset of response (CR/PR) to progression or death from any cause
|
Approximately 4 years
|
|
Overall Survival
大体时间:Approximately 4 years
|
Overall survival is defined as the time from date of start of treatment to date of death due to any cause.
If a patient is not known to have died, survival will be censored at the date of last contact.
|
Approximately 4 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CRAD001LIC01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.